

**UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION**

COMMISSIONERS: **Lina M. Khan, Chair
Rebecca Kelly Slaughter
Alvaro M. Bedoya**

In the Matter of

**Amgen Inc.,
a corporation,**

and

**Horizon Therapeutics plc,
a corporation,**

Respondents.

DOCKET NO. 9414

PUBLIC

**JOINT MOTION TO CONTINUE THE ADMINISTRATIVE HEARING
UNTIL NOVEMBER 8, 2023**

Complaint Counsel and Respondents respectfully submit this Joint Motion to Continue the Administrative Hearing until November 8, 2023.

In light of the case management and scheduling order in the federal Section 13(b) proceeding, Complaint Counsel and Respondents request a short continuance of the start of the evidentiary hearing in the administrative proceeding (currently slated to begin on October 25, 2023) until November 8, 2023. The Section 13(b) evidentiary hearing (FTC v. Amgen Inc., No. 3:23-cv-03053 (N.D. Ill.)) is scheduled to take place in Chicago, Illinois between September 11-22, 2023, and post-hearing findings of fact and conclusions of law are due in that matter on September 29, 2023. At a status conference on May 23, 2023, the District Court expressed its intention to deliver by October 31, 2023, its ruling on the request for a preliminary injunction pursuant to Section 13(b).

Given that the federal court may rule in late October, and that Complaint or Respondents'

counsel may need to seek emergency appellate relief following the District Court's decision, the federal court proceeding presents conflicts in late October that would make it difficult for Complaint and Respondent counsel to begin the administrative hearing prior to November 8, 2023.

The parties thus request a short continuance of the start of the administrative hearing until November 8, 2023, which will enable the evidentiary hearing regarding the preliminary injunction to proceed before the administrative hearing, and avoid scheduling conflicts of counsel, while entailing only minimal delay in the administrative proceedings.

Dated: July 21, 2023

Respectfully submitted,

/s/ Nathan Brenner

Nathan Brenner
Anjelica Sarmiento
Federal Trade Commission
600 Pennsylvania Ave., NW
Washington, D.C. 20024

Counsel Supporting the Complaint

/s/ David R. Marriott

David R. Marriott
dmarriott@cravath.com
CRAVATH, SWAINE & MOORE LLP
825 Eighth Avenue
New York, New York 10019
Telephone: (212) 474-1000
Facsimile: (212) 474-3700

Counsel for Respondent Amgen Inc.

/s/ Ethan Glass

Ethan Glass
eglass@cooley.com
COOLEY LLP
1299 Pennsylvania Avenue, NW, Suite
700
Washington, DC 20004
Telephone: (202) 842-7800
Facsimile: (202) 842-7899

*Counsel for Respondent Horizon
Therapeutics plc*

**UNITED STATES OF AMERICA
BEFORE THE FEDERAL TRADE COMMISSION**

COMMISSIONERS: **Lina M. Khan, Chair**
 Rebecca Kelly Slaughter
 Alvaro M. Bedoya

In the Matter of

**Amgen Inc.,
a corporation,**

and

**Horizon Therapeutics plc,
a corporation,**

Respondents.

DOCKET NO. 9414

**[PROPOSED] ORDER ON JOINT MOTION TO CONTINUE
THE ADMINISTRATIVE HEARING UNTIL NOVEMBER 8, 2023**

On July 21, 2023, the parties filed a joint motion to continue the administrative hearing. Accordingly,

IT IS HEREBY ORDERED, that the hearing in this proceeding is rescheduled to begin on November 8, 2023.

By the Commission.

April J. Tabor
Secretary

ISSUED:

CERTIFICATE OF SERVICE

I hereby certify that on July 21, 2023, I filed the foregoing document electronically using the FTC's E-Filing System, which will send notification of such filing to:

April Tabor
Secretary
Federal Trade Commission
600 Pennsylvania Ave., NW, Rm. H-113
Washington, DC 20580
ElectronicFilings@ftc.gov

The Honorable D. Michael Chappell
Administrative Law Judge
Federal Trade Commission
600 Pennsylvania Ave., NW, Rm. H-110
Washington, DC 20580

I also certify that I caused the foregoing document to be served via email to:

David Marriott
Timothy Cameron
Daniel Zach
Jesse Weiss
Renata Hesse
Samantha Hynes
dmarriott@cravath.com
tcameron@cravath.com
dzach@cravath.com
jweiss@cravath.com
hesser@sullcrom.com
hyness@sullcrom.com
Cravath, Swaine & Moore LLP
825 Eighth Avenue
New York, NY 10019
Sullivan & Cromwell LLP
1700 New York Ave NW #700
Washington, DC 20006

*Counsel for Respondent
Amgen Inc.*

Ethan Glass
Jacqueline Grise
David Burns
eglass@cooley.com
jgrise@cooley.com
dburns@cooley.com

Cooley LLP
1299 Pennsylvania Avenue, NW
Suite 700
Washington, DC 20004-2400

*Counsel for Respondent
Horizon Therapeutics plc*

Date: July 21, 2023

By: s/ Nathan Brenner
Nathan Brenner

Counsel Supporting the Complaint